Latin American consensus on uncomplicated recurrent urinary tract infection—2018
- 58 Downloads
An estimated 20–30% of adult women who experience an initial urinary tract infection (UTI) will have recurrent infection. In these patients, prophylaxis may be considered to improve their quality of life and control overuse of antibiotics. Despite this need, there is currently no Latin American consensus on the treatment and prophylaxis of recurrent UTIs. This consensus, signed by a panel of regional and international experts on UTI management, aims to address this need and is the first step toward a Latin American consensus on a number of urogynecological conditions. The panel agrees that antibiotics should be considered the primary treatment option for symptomatic UTI, taking into account local pathogen resistance patterns. Regarding prophylaxis, immunoactive therapy with the bacterial lysate OM-89 received a grade A recommendation and local estrogen in postmenopausal women grade B recommendation. Lower-grade recommendations include behavior modification and D-mannose; probiotics (Lactobacilli), cranberries, and hyaluronic acid (and derivatives) received limited recommendations; their use should be discussed with the patient. Though considered effective and receiving grade A recommendation, antimicrobial prophylaxis should be considered only following prophylaxis with effective non-antimicrobial measures that were not successful and chosen based on the frequency of sexual intercourse and local pathogen resistance patterns.
KeywordsCystitis Recurrent uncomplicated UTI Immunotherapy Prophylaxis Antimicrobial resistance Non-antimicrobial prophylaxis
The meeting was supported by OM Pharma, a company of Vifor Pharma Group. English language writing and editorial assistance was provided by Daniel Guns of Intelligens Life Ltd.
The meeting was supported by Vifor Pharma Group. Writing assistance was funded by OM Pharma.
Compliance with ethical standards
Conflicts of interest
JHM has received speaker fees from OM Pharma.
EU has no relevant conflicts of interest to disclose.
OSC has received speaker fees from OM Pharma.
MM has no relevant conflicts of interest to disclose.
JG has no relevant conflicts of interest to disclose.
SRC has no relevant conflicts of interest to disclose.
ET has no relevant conflicts of interest to disclose.
PKM has no relevant conflicts of interest to disclose.
ECP has received speaker fees from OM Pharma.
- 5.Centre for Evidence-Based Medicine. Oxford Centre for Evidence-based Medicine – Levels of Evidence (March 2009). 2009. https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/. Accessed 8 July 2019.
- 6.European Association of Urology. EAU Guidelines on Urological Infections 2011. 2011. http://uroweb.org/wp-content/uploads/17_Urological-infections_LR-II.pdf. Accessed 8 July 2019.
- 7.European Association of Urology. EAU Urological Infections Guidelines 2019. 2019. https://uroweb.org/guideline/urological-infections/. Accessed 8 July 2019.
- 8.Kranz J, Schmidt S, Lebert C, Schneidewind L, Mandraka F, Kunze M, et al. The 2017 update of the German clinical guideline on epidemiology, diagnostics, therapy, prevention, and management of uncomplicated urinary tract infections in adult patients: part 1. Urol Int. 2018;100:263–70.CrossRefGoogle Scholar
- 9.Tavares W, Lopes HV, Castro R, Poli M, Sartori M, Girão M, Lorenzetti F, Simões R. Cistite recorrente: tratamento e prevenção. https://diretrizes.amb.org.br/ans/cistite_recorrente-tratamento_e_prevencao.pdf. Accessed 8 July 2019.
- 10.Del Pilar Velazquez M, Romero Nava LE, Lopez de Avalos DR, et al. Clinical practice guidelines. Recurrent infection of the urinary tract in women. Colegio Mexicano de Especialistas en Ginecología y Obstetricia. Ginecol Obstet Mex. 2010;78:S437–59.Google Scholar
- 16.Rubin RH, Shapiro ED, Andriole VT, Davies RJ, Stamm WE, with modifications by a European WorkingParty (Norrby SR). General guidelines for the evaluation of new anti-infective drugs for the treatment ofUTI. Taufkirchen, Germany: The European Society of Clinical Microbiology and Infectious Diseases,1993;294-310.Google Scholar
- 17.U.S. Department of Health and Human Services Center for Drug Evaluation and Research. Uncomplicated urinary tract infections: developing drugs for treatment guidance for industry. 2018. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm607095.pdf. Accessed 8 July 2019.
- 18.U.S. Department of Health and Human Services Center for Drug Evaluation and Research. Complicated Urinary Tract Infections: Developing Drugs for Treatment Guidance for Industry 2018. 2018. https://www.fda.gov/downloads/Drugs/Guidances/ucm070981.pdf. Accessed 8 July 2019.
- 19.European Association of Urology. EAU Guidelines on Urological Infections 2018. 2018 http://uroweb.org/guideline/urological-infections/. Accessed 8 July 2019.
- 20.European Association of Urology. EAU Guidelines on Urological Infections 2015. 2015. http://uroweb.org/wp-content/uploads/EAU-Guidelines-Urological-Infections-v2.pdf. Accessed 8 July 2019.
- 21.Campo-Urbina ML, Ortega- Ariza N, Parody-Munoz A, Gomez- Rodriguez LDC. Caracterización y perfil de susceptibilidad de uropatógenos asociados a la presencia de bacteriuria asintomática en gestantes del departamento del Atlántico, Colombia, 2014-2015.Estudio de corte transversal. Rev Colomb Obstet Ginecol. 2017, 68 (1):62–70.Google Scholar
- 22.Ambuila González E, Ramírez López L, Escobar Bedoya A, Chávez Vivas M. Prevalencia de uropatógenos Gram negativo aislados de pacientes adultos en la ciudad de Cali. Ciencia Salud. 2015;4:11–7.Google Scholar
- 23.Orrego-Marin CP, Henao-Mejia CP, Cardona-Arias JA. Prevalencia de infección urinaria, uropatógenos y perfil de susceptibilidad antimicrobiana. Acta Medica Colombiana. 2014;39:352–8.Google Scholar
- 24.Córdova E, Lespada MI, Cecchini D, et al. Prevalencia de gérmenes multirresistentes en infecciones del tracto urinario de la comunidad y asociadas a los cuidados de la salud. Actual SIDA Infectol. 2014;22:33–8.Google Scholar
- 32.Basacopol A, Carantino A, Popescu C, Ambert L. Immunostimulation with a lyophilized bacterial lysate (Bronchovaxom) in patients with chronic suppurative processes of the respiratory tract. Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol. 1986;35:39–44.Google Scholar
- 39.Godaly G, Ambite I, Svanborg C. Innate immunity and genetic determinants of urinary tract infection susceptibility. Curr Opin Infect Dis. 2015;28:88–96.Google Scholar
- 41.Wagenlehner FEM, Hoyme U, Kaase M, Fünfstück R, Naber KG, Schmiemann G. Uncomplicated urinary tract infections. Dtsch Arztebl Int. 2011;108:415–23.Google Scholar
- 43.Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52:e103–20.CrossRefGoogle Scholar
- 44.European Association of Urology. EAU Guidelines on Urological Infections Guidelines 2017. 2017. http://uroweb.org/wp-content/uploads/19-Urological-infections_2017_web.pdf. Accessed 8 July 2019.
- 55.Albert X, Huertas I, Pereiró II, Sanfélix J, Gosalbes V, Perrota C. Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev. 2004;3:CD001209.Google Scholar
- 58.De Cueto M, Aliaga L, Alós JI, Canut A, Los-Arcos I, Martínez JA, et al. Executive summary of the diagnosis and treatment of urinary tract infections: guidelines of the Spanish Society of Clinical Microbiology and Infections Diseases (SEIMC). Enferm Infecc Microbiol Clin. 2017;35:314–20.CrossRefGoogle Scholar
- 63.Perrotta C, Aznar M, Mejia R, Albert X, Ng CW. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane Database Syst Rev. 2008;16:CD005131Google Scholar
- 64.Jepson RG, Williams G, Craig JC. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2012;10:CD001321.Google Scholar
- 65.Schwenger EM, Tejani AM, Loewen PS. Probiotics for preventing urinary tract infections in adults and children. Cochrane Database Syst Rev. 2015;12:CD008772.Google Scholar
- 67.Asma B, Vicky L, Stephanie D, Yves D, Amy H, Sylvie D. Standardised high dose versus low dose cranberry proanthocyanidin extracts for the prevention of recurrent urinary tract infection in healthy women [PACCANN]: a double blind randomised controlled trial protocol. BMC Urol. 2018;18:29.CrossRefGoogle Scholar
- 71.Lee B, Bhuta T, Craig J, Simpson J. Methenaminahippurate for preventing urinary tract infections. Cochrane Database Syst Rev.2002; (1):CD003265 Google Scholar